Page last updated: 2024-12-09

2-(4-methoxyphenyl)-1-(2-methylprop-2-enyl)benzimidazole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

## 2-(4-methoxyphenyl)-1-(2-methylprop-2-enyl)benzimidazole

This compound is a benzimidazole derivative with a specific molecular structure:

* **Benzimidazole core:** A nitrogen-containing heterocyclic ring system, common in pharmaceuticals.
* **Methoxyphenyl substitution:** A phenyl group with a methoxy (OCH3) substituent, which can influence the compound's properties.
* **2-methylprop-2-enyl substitution:** A side chain with a double bond (alkene) and a methyl group. This can affect the molecule's shape and reactivity.

**Importance for Research:**

Specific research interests surrounding this compound may vary, but generally, benzimidazoles have a wide range of biological activities, including:

* **Anti-cancer properties:** Several benzimidazole derivatives have shown promising activity against different types of cancer. The methoxyphenyl and 2-methylprop-2-enyl substituents may modify the compound's interaction with specific cancer targets.
* **Antimicrobial activity:** Benzimidazoles are known to possess antibacterial and antifungal properties. This compound might exhibit improved efficacy or target different pathogens due to its unique structure.
* **Anti-inflammatory activity:** Benzimidazoles can modulate inflammatory processes. This specific derivative might offer specific anti-inflammatory effects due to its substituents.
* **Other therapeutic potential:** The compound could be explored for its potential in areas like anti-viral, anti-parasitic, or neuroprotective research.

**Research areas of interest:**

* **Structure-activity relationship:** Understanding how the specific substituents on the benzimidazole core influence the compound's biological activity.
* **Synthesis and optimization:** Developing efficient synthetic methods to produce the compound and explore structural variations.
* **Pharmacological studies:** Evaluating the compound's efficacy, mechanism of action, and potential toxicity in various in vitro and in vivo models.
* **Drug development:** Furthering the research to potentially develop this compound into a new therapeutic agent.

**Overall, the specific importance of 2-(4-methoxyphenyl)-1-(2-methylprop-2-enyl)benzimidazole lies in its potential for development as a new drug or research tool, given the wide range of biological activities associated with benzimidazole derivatives.** However, further research is needed to fully understand its properties and applications.

Cross-References

ID SourceID
PubMed CID661309
CHEMBL ID1334561
CHEBI ID112173

Synonyms (15)

Synonym
AKOS001138800
MLS000037195 ,
smr000041990
NCGC00020297-01
CHEBI:112173
2-(4-methoxyphenyl)-1-(2-methylprop-2-enyl)benzimidazole
NCGC00020297-02
STK738152
2-(4-methoxyphenyl)-1-(2-methylprop-2-en-1-yl)-1h-benzimidazole
CCG-142723
HMS2306C03
CHEMBL1334561
Q27192275
2-(4-methoxyphenyl)-1-(2-methylprop-2-en-1-yl)-1h-1,3-benzodiazole
Z57300225
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
benzimidazolesAn organic heterocyclic compound containing a benzene ring fused to an imidazole ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (13)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency23.93410.007215.758889.3584AID588342
glp-1 receptor, partialHomo sapiens (human)Potency31.62280.01846.806014.1254AID624417
ClpPBacillus subtilisPotency15.84891.995322.673039.8107AID651965
phosphopantetheinyl transferaseBacillus subtilisPotency79.43280.141337.9142100.0000AID1490
TDP1 proteinHomo sapiens (human)Potency13.78820.000811.382244.6684AID686978; AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency0.50120.180013.557439.8107AID1460
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency19.95260.011212.4002100.0000AID1030
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency12.58930.00137.762544.6684AID914; AID915
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency11.22020.28189.721235.4813AID2326
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency22.38720.035520.977089.1251AID504332
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency25.11890.001815.663839.8107AID894
huntingtin isoform 2Homo sapiens (human)Potency22.38720.000618.41981,122.0200AID1688
gemininHomo sapiens (human)Potency29.09290.004611.374133.4983AID624296
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]